Twice-yearly drug eases symptoms in chronic rhinosinusitis with polyps
An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...
Daily18h
USFDA accepts GSK depemokimab applications for review for asthma, chronic rhinosinusitis
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...
Pharmabiz22h
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...
GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report
The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...
GSK Pharma put volume heavy and directionally bearish
Pharma with 4,314 puts trading, or 4x expected. Most active are Mar-25 38.5 puts and Apr-25 37 puts, with total ...